Atlas FDA

UroVysion Bladder Cancer Kit

FDA premarket approval P030052/S026 · decided 2019-08-26

Approval details

PMA number
P030052
Supplement
S026
Supplement type
30-Day Notice
Supplement reason
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Trade name
UroVysion Bladder Cancer Kit
Generic name
System, test, tumor marker, for detection of bladder cancer
Applicant
Abbott Molecular
Date received
2019-07-31
Decision date
2019-08-26
Days to decision
26 days
Decision code
OK30
Product code
NAH
Advisory committee
Pathology
Expedited review
No
Location
Des Plaines, IL
Statement
Update to software.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
simpli-COLLECT STI Test (K243410)Abbott Molecular2025-01-30
Alinity m SARS-CoV-2 AMP Kit (09N78-096); Alinity m SARS-CoV-2 CTRL Kit (09N78-086) (K241580)Abbott Molecular2024-12-06